Betanin inhibits PI3K/AKT/mTOR/S6 signaling pathway, cell growth and death in osteosarcoma MG‐63 cells

Author:

Liu Jichao1,Velu Periyannan2ORCID,Vijayalakshmi Annamalai3ORCID,Zareian Mohsen4,Xi Haitao5ORCID

Affiliation:

1. Department of Hand and Foot Micro Burn Plastic Surgery 3201 Hospital Hanzhong China

2. Department of Biochemistry and Biotechnology Annamalai University Chidambaram India

3. PG and Research Department of Biochemistry Rabiammal Ahamed Maideen College for Women Tiruvarur India

4. Department of Life Sciences Chalmers University of Technology Göteborg Sweden

5. Department of Orthopeadic Surgery Area 2 Xi'an NO.3 Hospital Xi'an China

Abstract

AbstractIt is possible to develop new chemopreventive compounds so that cancer cells can be targeted in an exclusive manner. Bioactive natural compounds have demonstrated to be efficient chemotherapeutic agents, safe and cost‐effective. Majority of anti‐cancer medications are derived from natural sources, particularly of plant origins. Betanin (betanidin‐5‐O‐β‐glucoside) is the most common betacyanin with antioxidant, anti inflammatory and anticancer properties. The present study therefore investigated the effect of betanin onosteosarcoma MG‐63 cells. The mechanistic pathway of inflammatory responses, cell proliferation and apoptosis were investigated. The MG‐63 cells were treated with betanin for 24 h. Betanin actions on the appearance of cell arrangements, morphological changes, ROS induced Δψm, cell migration, cell adhesion and proliferative mechanistic marker expression of PI3K/AKT/mTOR/S6were analyzed. Betanin inhibited MG‐63 cells at IC50 concentrations between 9.08 and 54.49 μM and induced apoptosis by triggering the ROS mechanism. Betanin inhibited proliferation and migration of MG‐63 cells and induced DNA fragmentation. Betanin also modified the key mediator expression levels of PI3K/AKT/mTOR/S6 signaling pathways. Betanin can potentially be utilized in bone carcinoma therapeutics to inhibit, reverse or delay osteosarcoma.

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Management, Monitoring, Policy and Law,Toxicology,General Medicine

Reference28 articles.

1. Osteosarcoma in patients below 25 years of age: an observational study of incidence, metastasis, treatment and outcomes;Nie Z;Oncol Lett,2018

2. Osteosarcoma incidence and survival rates from 1973 to 2004

3. Epidemiology and Risk Factors of Osteosarcoma

4. Osteosarcoma: a review of current and future therapeutic approaches

5. Limb‐salvage surgery offers better five‐year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta‐analysis.J bone;Papakonstantinou E;Oncologia,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3